Figure 1, Figure 2 and Figure 3 show that EGCG directly inhibits PD-L1 expression and JAK-STAT signaling in tumor cells, which would re-activate T cells. In contrast, the anti-PD-1 antibody treatment directly blocks the PD-L1-mediated inhibitory signals to T cells. Therefore, we compared the effects of EGCG and the anti-PD-1 antibody treatment on CD8+ cells (Figure 4C–F). This evidence concerns the gene CD8A and neoplasm.